Genomic profiling is essential for accurate and rapid diagnosis and prognosis of myeloid neoplasms such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasm (MPN).
Conventional testing methods (such as chromosomal assays) are subjective and present a diagnostic challenge in myeloid tumors from bone marrow specimens, leading to wide inter-observer variability in the quantification of dysplastic and blast cells, resulting in long turnaround times. We offer both next-generation sequencing (NGS) and single-gene testing to help determine the treatment and monitoring of myeloproliferative disorders with a fast turnaround time of two weeks.
Meyloid Molecular Profiling
NGS Panels-Background and Test Information
Leveraging the power of NGS technology, Anwa Myeloid Molecular NGS Profile provides a comprehensive assessment of 40 key genes and a broad fusion panel of 29 driver genes including ABL1, BRAF,CBL,KRAS,MPL, NRAS,IDH1,IDH2,JAK2,FLT3. The panel covers the most relevant targets in the major myeloid disorders: acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML).
40 key genes
29 fusion transcripts
10 working days
Myeloid Molecular Profiling
Single Gene Testing-Background and Test Information
We also offer many single-gene tests that allow for accurate diagnosis, treatment selection, and patient monitoring.
Single gene tests:
FLT3, NPM1, JAK2, MPL, CEBPA, IDH1/2, TP53, PML-RARA, RUNX1-RUNX1T1, and BCR-ABL (p190, p210, p230)
10 working days